BRAINSTORM CELL THERAPEUTICS INC. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD from Q3 2018 to Q3 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
-
Summary
-
Brainstorm Cell Therapeutics Inc. quarterly/annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect history and growth rate from Q3 2018 to Q3 2024.
- Brainstorm Cell Therapeutics Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending September 30, 2024 was -$3.3M, a 588% decline year-over-year.
- Brainstorm Cell Therapeutics Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the twelve months ending September 30, 2024 was -$873K, a 70.1% increase year-over-year.
- Brainstorm Cell Therapeutics Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2023 was $713K.
- Brainstorm Cell Therapeutics Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2022 was -$18.1M, a 4.69% increase from 2021.
- Brainstorm Cell Therapeutics Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2021 was -$19M, a 151% decline from 2020.
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Trailing 12 Months (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Growth (%)